

Etienne Brain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7603427/publications.pdf>

Version: 2024-02-01

59
papers

4,974
citations

304743

22
h-index

168389

53
g-index

62
all docs

62
docs citations

62
times ranked

6868
citing authors

#	ARTICLE	IF	CITATIONS
1	70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729.	27.0	1,427
2	International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2595-2603.	1.6	1,380
3	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology</i> , The, 2012, 13, e148-e160.	10.7	505
4	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
5	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
6	Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. <i>Annals of Oncology</i> , 2014, 25, 1979-1987.	1.2	122
7	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
8	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. <i>European Journal of Cancer</i> , 2020, 129, 60-70.	2.8	103
9	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 429-437.	2.5	99
10	Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. <i>Lancet Oncology</i> , The, 2018, 19, 323-336.	10.7	94
11	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	7.1	92
12	Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6731-6741.	7.0	53
13	Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. <i>Cancer Treatment Reviews</i> , 2016, 43, 19-26.	7.7	51
14	Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. <i>Breast Cancer Research</i> , 2019, 21, 121.	5.0	42
15	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	1.0	40
16	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 125, 69-82.	2.8	36
17	Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 624-635.	1.6	35
18	Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , 2021, 7, 41.	5.2	33

#	ARTICLE	IF	CITATIONS
19	Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. <i>European Journal of Cancer</i> , 2020, 125, 22-30.	2.8	31
20	Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial. <i>British Journal of Cancer</i> , 2021, 124, 1207-1213.	6.4	31
21	Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer. <i>European Journal of Cancer</i> , 2018, 90, 10-18.	2.8	30
22	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	2.8	25
23	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	7.0	23
24	Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer—patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. <i>European Journal of Cancer</i> , 2017, 75, 323-332.	2.8	22
25	Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. <i>European Journal of Radiology</i> , 2021, 141, 109821.	2.6	19
26	Impact of body mass index on overall survival in patients with metastatic breast cancer. <i>Breast</i> , 2021, 55, 16-24.	2.2	17
27	Plasma thymidine kinase 1 activity and outcome of ER+ HER2+ metastatic breast cancer patients treated with palbociclib and endocrine therapy. <i>Breast Cancer Research</i> , 2020, 22, 98.	5.0	16
28	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2017, 86, 240-247.	2.8	14
29	Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study. <i>European Journal of Cancer</i> , 2022, 164, 70-79.	2.8	14
30	Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 3681.	3.7	13
31	Taking care of older patients with cancer in the context of COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2020, 21, e236.	10.7	13
32	Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. <i>Genome Medicine</i> , 2021, 13, 44.	8.2	13
33	The SIOG COVID-19 working group recommendations on the rollout of COVID-19 vaccines among older adults with cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 848-850.	1.0	11
34	Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology. <i>European Journal of Cancer</i> , 2018, 103, 120-126.	2.8	8
35	UCBC 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2+ positive subgroup. <i>European Journal of Cancer</i> , 2019, 122, 91-100.	2.8	8
36	Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey. <i>Cancers</i> , 2019, 11, 1955.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020, 12, 3509.	3.7	7
38	VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapyâ€”A Message from COMET, a French Unicancer Multicentric Study. <i>Pharmaceuticals</i> , 2020, 13, 414.	3.8	6
39	Optimal duration of adjuvant chemotherapy for high-risk node-negative (Nâ€“) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). <i>European Journal of Cancer</i> , 2017, 79, 166-175.	2.8	5
40	Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. <i>Anticancer Research</i> , 2020, 40, 3905-3913.	1.1	5
41	Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. <i>Breast</i> , 2021, 60, 138-146.	2.2	5
42	Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. <i>Breast</i> , 2022, 64, 100-111.	2.2	5
43	Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial. <i>Journal of Geriatric Oncology</i> , 2022, 13, 582-593.	1.0	4
44	Real-world evidence of the management and prognosis of young women (â©½40â€%years) with de novo metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110703.	3.2	4
45	Geriatric impairments were directly and indirectly associated with mortality in older patients with cancer: a structural equation analysis. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 17-26.	5.0	4
46	Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts. <i>Cancers</i> , 2021, 13, 6154.	3.7	4
47	Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. <i>European Journal of Cancer</i> , 2022, 172, 158-170.	2.8	4
48	New Frontiers for Fairer Breast Cancer Care in a Globalized World. <i>The Journal of Breast Health</i> , 2021, 17, 86-94.	1.0	3
49	Breast cancer in older women: predicting adjuvant benefit. <i>Lancet Oncology</i> , The, 2014, 15, 672-674.	10.7	1
50	Preferences for surrogate designation and decision-making process in older versus younger adults with cancer: A comparative cross-sectional study. <i>Patient Education and Counseling</i> , 2019, 102, 429-435.	2.2	1
51	Perspectives on cancer care in older patients in France. <i>Ecancermedicalsecience</i> , 2020, 14, 1103.	1.1	1
52	Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098054.	3.2	1
53	A call for specific geriatric data on cervical cancers. <i>Future Oncology</i> , 2016, 12, 1101-1104.	2.4	0
54	4th symposium on primary breast cancer in older women. Theme: putting personalized care into practice (Held: 3 March 2017). <i>Breast Cancer Management</i> , 2017, 6, 33-53.	0.2	0

#	ARTICLE	IF	CITATIONS
55	AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo controlled, multinational phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Journal of Clinical Oncology, 2018, 36, TPS1109-TPS1109.	1.6	0
56	Early-Stage Breast Cancer in Older Adults. , 2019, , 1-10.		0
57	Early-Stage Breast Cancer in Older Adults. , 2020, , 633-642.		0
58	Tumors: Breast. , 2020, , 1-8.		0
59	Tumors: Breast. , 2021, , 5215-5222.		0